 Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safetyefficacy trials for men and women. AbbVie led Androgel 1.62 5,246-participant cardiovascular safety trial is also measuring efficacy for dysthymia, clinical fractures, anemia, and progression from pre-diabetes to diabetes, results could lead to sNDA submissions. 